Please assess the completion status of the following clinical trial:

Trial Title: Whole Brain Radiotherapy With or Without Temozolomide at Daily Fixed-dose for Brain Metastases Treatment

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Karnofsky performance status (KPS) ≥ 50~* Life expectancy ≥ 12 weeks~* Histologically confirmed non lymphomatous solid tumors at primary site~* Brain metastases diagnosed with cranial MRI/CT.~* Extracranial metastases or primary tumor uncontrolled are allowed~* Hemoglobin ≥ 10 g/dl~* Absolute neutrophil count of \> 1500/mm3~* Platelet count of ≥ 100,000/mm3~* Blood urea nitrogen (BUN) ≤ 25 mg/dl,~* Serum creatinin ≤ 1.5 mg/dl~* Serum bilirubins ≤ 1.5 mg/dl,~* Alanine aminotransferase (ALT) and Aspartate aminotransferase (AST) ≤ twice the upper normal limit~Exclusion Criteria~* Pregnant or breast feeding woman~* History of allergic reaction to iodinated contrast media~* Inability to swallow~* Systemic chemotherapy in previous 3 weeks~* Oral chemotherapy in previous 2 weeks~* Prior surgery, chemotherapy, or radiotherapy for a brain neoplasm~* Meningeal carcinomatosis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Whole brain irradiation plus Temozolomide (Type: EXPERIMENTAL): Whole brain irradiation at a dose of 30 Gy in 10 daily fractions over 2 weeks, and a fixed dose of oral Temozolomide, 1h before each fraction of whole brain irradiation, 200 mg on Monday, Wednesday, Friday; 300 mg on Tuesday, and Thursday. Without adjuvant cycles of Temozolomide.
- Whole brain irradiation (Type: ACTIVE_COMPARATOR): Whole brain irradiation at a dose of 30 Gy in 10 daily fractions over 2 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).